Introduction
Neuregulin-1, a subfamily of the epidermal growth factor family, plays a role in the development of the peripheral nervous system (Birchmeier and Nave, 2008; Newbern and Birchmeier, 2010) . The neuregulin-1 gene encodes an entire family of more than 15 transmembrane and secreted isoforms via alternative RNA splicing and promoter usage (Falls, 2003a; Hu et al., 2006) . All of these isoforms contain an epidermal growth factor-like domain, which alone is sufficient to bind and activate ErbB receptor tyrosine kinases, and can be classified into three subgroups (type I, II, III) according to the N-terminal sequence. Types I and II, containing Ig-like domain (types I, II) called "Ig-neuregulins," can either be directly secreted or can be released as soluble proteins from the cell surface following proteolytic cleavage (Falls, 2003b) . Type III, containing a cysteine-rich domain called "cysteine-rich domain-neuregulins," require proteolytic cleavage for full activity and signal in a juxtacrine fashion (Hu et al., 2006) .
Numerous studies have demonstrated that neuregulin-1 acts as a vital regulator at many stages of the Schwann cell lineage through binding to ErbB receptors, including the survival of Schwann cell precursors, Schwann cell proliferation, motility, axon ensheathment and myelination (Garratt et al., 2000a, b; Nave and Salzer, 2006; Birchmeier and Nave, 2008; Limpert and Carter, 2010; Syed et al., 2010; Heermann et al., 2011) . Targeted ablation of the neuregulin-1 gene or its receptors resulted in severe deficiency of Schwann cells, which demonstrated the importance of neuregulin-1 in the Schwann cell lineage (Meyer and Birchmeier, 1995; Lyons et al., 2005; Atanasoski et al., 2006; Fricker et al., 2009) . Specific knockout of neuregulin-1 type III demonstrated that type III is the key isoform required for Schwann cell generation (Wolpowitz et al., 2000) . Recent studies have confirmed that the level of axon-derived neuregulin-1 type III provides an instructive signal for Schwann cells committing to a myelinating fate and regulating myelin sheath thickness (Michailov et al., 2004; Taveggia et al., 2005; Chen et al., 2006) . Knockout of neuregulin-1 type III in adults showed no significant differences in G-ratio and axon diameter, indicating that neuregulin-1 type III is unnecessary for maintenance of the myelin sheath in adult animals (Fricker et al., 2011) .
At present, the expression pattern of neuregulin-1 type III in the peripheral nervous system during development has never been studied in vivo. Of interest is whether neuregulin-1 type III would be up-regulated during the myelinating stage and down-regulated in the following stages.
We examined the patterns of expression of neuregulin-1 type III during specific developmental periods in an attempt to gain a better understanding of interactions between glial cells and neurons that are responsible for myelination and myelin sheath maintenance. We analyzed the mRNA and protein expression levels of neuregulin-1 type III of intact rat dorsal root ganglia isolated at developmental time points ranging from postnatal day 1 to postnatal day 56 by quantitative real-time polymerase chain reaction and western blot assay. Additionally, we used immunofluorescent staining to detect the pattern of neuregulin-1 type III protein expression.
Materials and Methods

Experimental animals
Postnatal Sprague-Dawley rats were provided by the Experimental Animal Center of the Fourth Military Medical University of Chinese PLA (Xi'an, Shaanxi Province, China). All the experimental procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication No. 85-23, revised 1985) .
Isolation of rat dorsal root ganglia
Dorsal root ganglias were isolated from postnatal SpragueDawley rats (provided by the Experimental Animal Center of the Fourth Military Medical University of Chinese PLA) at various developmental time points ranging from postnatal day 1 to postnatal day 56 (at 1, 3, 7, 14, 28, 56 days) with 20 rats per time point, which encompasses the proliferating stage, the premyelinating stage, the myelinating stage and the postmyelinating stage (Reinhard et al., 2009) .
Total RNA isolation
Total RNA was isolated from dorsal root ganglias using the PARIS kit according to the manufacturer's instructions (Ambion Inc., Austin, Texas, USA). The RNA was placed on ice and a Beckman DU-600 spectrometer (Beckman coulter, San Francisco, California, USA) was used to measure RNA concentration and purity by comparing the A 260 nm /A 280 nm ratio. The RNA sample was then immediately stored at −80°C.
Quantitative real-time polymerase chain reaction
The total RNA isolated from dorsal root ganglias at various developmental time points was used for quantitative real-time polymerase chain reaction. The cDNA was synthesized using Superscript III reagents according to the manufacturer's instructions (Invitrogen Corp., Carlsbad, CA, USA). The cDNA products were stored at −80°C until samples from all time points were ready to be analyzed. Quantitative real-time polymerase chain reaction was performed using an Eppendorf Master Cycler ep realplex Thermal Cycler and the iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions. The primer sequences used in this study are shown in Table 1 . Quantitative real-time polymerase chain reaction conditions were as follows: denaturation at 95°C for 30 seconds; primer annealing at 59°C for 30 seconds; and elongation at 72°C for 40 seconds. Quantification of PCR products was performed using the 2 -∆∆Ct method (Sun et al., 2003) . Quantities of mRNA were normalized to the housekeeping gene GAPDH. Assays were performed three times using triplicate wells.
Western blot assay
Dorsal root ganglias were isolated from rats at various developmental time points. Dorsal root ganglia homogenates were prepared by homogenizing dorsal root ganglias in 10 volumes of ice cold lysis buffer (50 mM Tris pH 7.4; 150 mM NaCl; 1% NP-40; 1 mM EDTA) containing protease inhibitors (100 μM Antipain; 5 μg/mL Leupeptin; 5 μg/mL Pepstatin). Lysates were incubated for 30 minutes at 4°C and centrifuged at 10,000 × g for 10 minutes at 4°C. Supernatants were collected and protein was quantified using the Bradford protein assay (Bio-Rad). Samples of 10 μg from each lysate were loaded on a 10% sodium dodecyl sulfate-polyacrylamide slab gel and transferred to nitrocellulose membranes (45 μm, Invitrogen Corp., Carlsbad, CA, USA) in 25 mM Trizma-base, 192 mM glycine and 20% methanol, pH 8.3, using a Mini Trans-Blot system (Bio-Rad) for 1 hour at 100 V. After blotting, membranes were blocked at 4°C overnight with 5% nonfat dry milk in Tris-buffered saline containing 0.1% Tween20 (TBST). Blots were then incubated at 4°C for 1 hour with rabbit anti-neuregulin-1 type III polyclonal antibody (1:1,000; Abcam Inc., UK). After rinsing membranes with TBST, secondary goat anti-rabbit antibody conjugated with horseradish peroxidase (1:2,000; Sigma, St. Louis, MO, USA) were incubated for 1 hour. Membranes were incubated in NEN luminal reagent (NEN TM Life Science Products) and exposed to X-ray film. The developed films were transilluminated and photographed with a Nikon 990 digital camera (Nikon Corporation, Chiyoda-ku, Tokyo, Japan). Densitometry of individual bands was performed using ImageJ software 1.46 m (http:// rsb.info.nih.gov/ij/). Values were normalized to the optical density of GAPDH. Results are representative of at least three trials from different dorsal root ganglia preparations for each developmental time point and for each antibody.
Immunohistochemistry
Dorsal root ganglias were isolated from rats at various developmental time points, post-fixed, and sectioned. Sections were subjected to immunofluorescent staining following a standard procedure. In brief, sections were incubated with 0.3% (v/v) Triton-X for 30 minutes and then blocked in 10% horse serum for 2 hours. The sections were then incubated with rabbit anti-neuregulin-1 type III polyclonal antibody (1:400; Abcam Inc.) and mouse anti-NF200 monoclonal antibody (1:200; Sigma) at 4°C for 24 hours. Next, the primary antibodies were probed with either indocarbocyanine-conju-gated goat anti-rabbit monoclonal antibody (1:1,000; Abcam Inc.) or fluorescein-conjugated goat anti-mouse monoclonal antibody (1:1,000; Abcam Inc.), and DAPI (10 μg/mL; Sigma), a fluorescent nuclear dye. All of the incubation steps, except the overnight incubation, were performed at room temperature. Samples were rinsed three times in PBS (pH 7.4) between each step. Sections were then examined under a laser confocal microscope (FV1000; Olympus, Tokyo, Japan). All images were taken under the same conditions and parameters. Red fluorescence intensity represented the expression level of neuregulin-1 type III protein.
Statistical analysis
All data were presented as the mean ± SD. One-way analysis of variance was used for statistical comparison of the means. Significant results were analyzed by Tukey's post hoc testing using GraphPad Prism for Windows, version 5.0 software (GraphPad Software, San Diego, CA, USA). A P value of less than 0.05 was considered statistically significant. The X-axis represents the different time points, and the Y-axis represents the ratio of mRNA levels from the postnatal day 3 to postnatal day 56 group (P-56) to the postnatal day 1 group (P-1). Bar graph: Data are expressed as the mean ± SD of three rats at each time point; *P < 0.05 and **P < 0.01. The results were performed by one-way analysis of variance followed by Tukey's post hoc test. P: Postnatal day. Data are expressed as the mean ± SD of three rats at each time point. *P < 0.05 and **P < 0.01. Results were performed by one-way analysis of variance followed by Tukey's post hoc test. P: Postnatal day; GAPDH: glyceraldehyde phosphate dehydrogenase. P-1 P-3 P-7 P-14 P-21 P-28 P-56 P-1 P-3 P-7 P-14 P-21 P-28 P-56 in Figure 1B . The mRNA levels of neuregulin-1 type III at different developmental time points from postnatal day 1 to postnatal day 56 were compared in Figure 2 . The expression of neuregulin-1 type III mRNA reached its peak at postnatal day 3 and then stabilized at a relatively high expression level from postnatal day 3 to postnatal days 56. The mRNA level of neuregulin-1 type III at postnatal days 3, 14 and 28 was higher (2.6-fold, 2.7-fold and 2.2-fold, respectively) than that at postnatal day 1 (Figure 2) . The mRNA level of neuregulin-1 type III at postnatal days 7, 21 and 56 appeared higher than that at postnatal day 1, but did not reach significance (P > 0.05). There was no significant difference of neuregulin-1 type III mRNA level from postnatal day 3 to postnatal day 56 (P > 0.05).
The protein levels of neuregulin-1 type III at different developmental time points
The expression of neuregulin-1 type III protein in dorsal root ganglias isolated at different developmental time points from postnatal day 1 to postnatal day 56 was investigated by western blot assay. As shown in Figure 3 , the densitometric results depicted the immunoreactivity of neuregulin-1 type III. The expression of neuregulin-1 type III increased gradually from postnatal day 1 to postnatal day 28, reached a peak at postnatal day 28, and then decreased at postnatal day 56. The expression of neuregulin-1 type III at postnatal days 14, 21, 28 and 56 was significantly higher (2.0-, 2.2-, 3.0-and 2.5-fold, respectively) when compared to that at postnatal day 1 (Figure 3) . In addition, the expression of neuregulin-1 type III at postnatal day 28 was also significantly higher than that at postnatal day 3 (P < 0.01). From postnatal day 1 to postnatal day 7, the expression of neuregulin-1 type III protein in dorsal root ganglias showed an obvious increasing tendency, but did not reach significance (P > 0.05). There was no significant difference in neuregulin-1 type III protein level between the other time points (P > 0.05).
Immunofluorescent staining of neuregulin-1 type III at different developmental time points
To further confirm the expression pattern of neuregulin-1 type III at different developmental time points, we utilized immunofluorescent staining. Neurofilament was used as a positive control and cell nuclei were labeled with DAPI. All images were taken under the same conditions and parameters. As shown in Figure 4 , the red fluorescence intensity represented the expression level of neuregulin-1 type III protein, which tended to increase gradually from postnatal day 1 to postnatal day 28, reached a peak at postnatal day 28, and then decreased at postnatal day 56. Thus, immunofluorescent staining results showed a similar tendency to the western blot assay results. In addition, big dorsal root ganglia neurons displayed higher fluorescence intensity than the small neurons.
Discussion
Neuregulin-1 is known to be involved in the development of the nervous system (Chen et al., 2003) ; however, different isoforms exhibit distinct cell specific function (Wen et al., Figure 4 Immunofluorescent staining of neuregulin-1 (NRG1) type III isolated from dorsal root ganglia at different developmental time points (A-G) under laser confocal microscopy. NRG1 type III expression was labeled with NRG1 type III (red). Neurofilament expression was labeled with NF-200 (green), and cell nuclei were labeled with DAPI (blue). Sections were stained following the same staining procedure, and all images were taken under the same conditions and parameters. Red fluorescence intensity represented the expression level of NRG1 type III protein, and tended to increase gradually from postnatal day 1 to postnatal day 28, reached a peak at postnatal day 28, and then decreased at postnatal day 56. Scale bars: 100 μm. P: Postnatal day.
1992; Marchionni et al., 1993; Canoll et al., 1996) . Neuregulin-1 type III is the key isoform required for Schwann cell proliferation, committing to a myelinating fate and regulating myelin sheath thickness (Garratt et al., 2000a; Taveggia et al., 2005; Birchmeier and Nave, 2008; Heermann et al., 2011) . However, limited information is available from previous studies regarding the expression pattern of neuregulin-1 type III in the peripheral nervous system during developmental periods (such as the premyelinating stage, myelinating stage and postmyelinating stage). In this study, we have examined the expression of neuregulin-1 type III in dorsal root ganglia neurons at various developmental stages to gain a better understanding of the interactions between glial cells and neurons that are responsible for myelination and myelin sheath maintenance.
In the postnatal period, Schwann cells experience several important stages, including the proliferating stage (postnatal day 0 to postnatal day 2), the premyelinating stage (postnatal day 2 to postnatal day 5) and the myelinating stage (postnatal day 5 to postnatal day 10; Martinez et al., 2004; Reinhard et al., 2009) . Thus, in the present study, we chose postnatal days 1, 3 and 7 as the time point which represented the proliferating stage, the premyelinating stage and the myelinating stage, respectively. In addition, postnatal day 14 to postnatal day 56 was chosen to represent the postmyelinating stage. Our results showed that neuregulin-1 type III had an increasing tendency from postnatal day 1 to postnatal day 14, which supported the view that neuregulin-1 type III synthesized by dorsal root ganglia neurons contributes to the signal that promotes the proliferation of Schwann cells from postnatal day 0 to postnatal day 2, and axonal myelination by Schwann cells from postnatal day 5 to postnatal day 15 (Birchmeier and Nave, 2008; Reinhard et al., 2009) .
Recent studies have provided compelling evidence that the level of axon-derived neuregulin-1 type III provides a key instructive signal for Schwann cell committing to a myelinating fate and regulating myelin sheath thickness (Michailov et al., 2004; Taveggia et al., 2005) . However, neuregulin-1 type III exerts no effect on the maintenance of the myelin sheath in adult animals (Atanasoski et al., 2006; Fricker et al., 2011) . To our surprise, the expression of neuregulin-1 type III was not decreased in the postmyelinating stage from postnatal day 14 to postnatal day 56, a relative high level of neuregulin-1 type III mRNA was also observed. Interestingly, neuregulin-1 type III protein increased gradually from postnatal day 14 to postnatal day 28 and reached a peak at postnatal day 28 which was confirmed using both western blot assay and immunofluorescent staining. The high expression of neuregulin-1 type III can account for the idea that axonally presented neuregulin-1 type III inhibits the expression of neuregulin-1 type I in Schwann cells (Stassart et al., 2013) . However, the exact role of neuregulin-1 type III in the mature peripheral nervous system has not been identified. This is an important question for further study.
The expression of neuregulin-1 type III mRNA reached a peak at postnatal day 3 and then stabilized at a relatively high expression level from postnatal day 3 to postnatal day 56. However, the expression of neuregulin-1 type III increased gradually from postnatal day 1 to postnatal day 28, reached a peak at postnatal day 28, and then decreased at postnatal day 56. Thus, there were no clear correlations between neuregulin-1 type III protein expression patterns and the mRNA levels at these developmental time points, indicating the importance of the translational control of neuregulin-1 type III expression.
In conclusion, this study has identified the expression pattern of neuregulin-1 type III in the peripheral nervous system during development. This study also confirmed a persistent expression of neuregulin-1 type III from postnatal day 14 to postnatal day 56, indicating a continued need for neuregulin-1 type III signaling in the mature nervous system. Further studies of neuregulin-1 type III in the postmyelinating stage would contribute to understanding the role of neuregulin-1 type III in physical and pathological conditions in matured nervous systems and help find new therapeutic approaches for nervous system diseases. 
